The Skp2-SCF E3 Ligase Regulates Akt Ubiquitination, Glycolysis, Herceptin Sensitivity, and Tumorigenesis  by Chan, Chia-Hsin et al.
The Skp2-SCF E3 Ligase Regulates
Akt Ubiquitination, Glycolysis,
Herceptin Sensitivity, and Tumorigenesis
Chia-Hsin Chan,1 Chien-Feng Li,5,6,11 Wei-Lei Yang,1,4 Yuan Gao,1,4 Szu-Wei Lee,1,4 Zizhen Feng,1 Hsuan-Ying Huang,7
Kelvin K.C. Tsai,6 Leo G. Flores,2 Yiping Shao,3 John D. Hazle,3 Dihua Yu,1,4 Wenyi Wei,8 Dos Sarbassov,1,4
Mien-Chie Hung,1,4,10 Keiichi I. Nakayama,9 and Hui-Kuan Lin1,4,*
1Department of Molecular and Cellular Oncology
2Department of Experimental Diagnostic Imaging
3Department of Image Physics
The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
4The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX 77030, USA
5Department of Pathology, Chi-Mei Foundational Medical Center, Tainan 710, Taiwan
6National Institute of Cancer Research, National Health Research Institutes, Tainan 704, Taiwan
7Department of Pathology, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine,
Kaohsiung County 833, Taiwan
8Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
9Department of Molecular and Cellular Biology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Fukuoka 812-8582, Japan
10Center for Molecular Medicine and Graduate Institute of Cancer Biology, China Medical University and Hospital, Taichung 404, Taiwan
11Department of Biotechnology, Southern Taiwan University, Tainan 710, Taiwan
*Correspondence: hklin@mdanderson.org
DOI 10.1016/j.cell.2012.02.065SUMMARY
Akt kinase plays a central role in cell growth, metab-
olism, and tumorigenesis. The TRAF6 E3 ligase
orchestrates IGF-1-mediated Akt ubiquitination and
activation. Here, we show that Akt ubiquitination is
also induced by activation of ErbB receptors; unex-
pectedly, and in contrast to IGF-1 induced activation,
the Skp2 SCF complex, not TRAF6, is a critical E3
ligase for ErbB-receptor-mediated Akt ubiquitination
andmembrane recruitment in response to EGF. Skp2
deficiency impairs Akt activation, Glut1 expression,
glucose uptake and glycolysis, and breast cancer
progression in various tumor models. Moreover,
Skp2 overexpression correlates with Akt activation
and breast cancer metastasis and serves as amarker
for poor prognosis in Her2-positive patients. Finally,
Skp2 silencing sensitizes Her2-overexpressing
tumors to Herceptin treatment. Our study suggests
that distinct E3 ligases are utilized by diverse growth
factors for Akt activation and that targeting glycol-
ysis sensitizes Her2-positive tumors to Herceptin
treatment.
INTRODUCTION
Akt kinase is a key factor that conveys growth factor signals from
outside the cell to inside the cell. It serves as a central node for
the regulation of cell proliferation, cell survival, metabolism,1098 Cell 149, 1098–1111, May 25, 2012 ª2012 Elsevier Inc.and tumorigenesis (Brazil et al., 2002; Liu et al., 2009; Manning
and Cantley, 2007; Yang et al., 2010a). The recruitment of Akt
kinase to the plasma membrane is a critical step for Akt phos-
phorylation and activation by growth-factor stimuli. Although
the PIP3 formation-induced by PI3K activation is essential for
Akt membrane recruitment, our recent study reveals that K63-
linked ubiquitination of Akt is also required for this process.
TRAF6 is found to be an ubiquitin ligase (E3) for Akt and plays
a crucial role in Akt ubiquitination, membrane translocation,
and phosphorylation upon stimulation with insulin-like growth
factor-1 (IGF-1) (Yang et al., 2009, 2010b). Thus, Akt ubiquitina-
tion and PIP3 binding are two important events required for Akt
membrane recruitment and activation in response to IGF-1.
However, it remains largely unclear whether Akt ubiquitination
is universally engaged in Akt membrane translocation and acti-
vation triggered by other growth factor receptors, such as
ErbB family.
Under normoxic condition, differentiated cells primarily utilize
mitochondria oxidative phosphorylation to generate adenosine
50-triphosphate (ATP) for biogenesis and cellular processes (Ara-
gone´s et al., 2009; Vander Heiden et al., 2009). However, under
hypoxia these cells switch their metabolism from aerobic oxida-
tive phosphorylation to anaerobic glycolysis. Notably, tumor
cells utilize aerobic glycolysis regardless of the oxygen levels,
known as the Warburg effect. The elevated aerobic glycolysis
seen in tumor cells rapidly generates ATP in order to meet their
increased need for energy and biosynthesis to sustain tumor
growth (Birnbaum, 2004; Plas and Thompson, 2005; Robey
and Hay, 2009). Akt kinase is frequently activated in various
tumor types and represents one of the main drivers for the
Warburg effect (Elstrom et al., 2004). Akt increases glucose
uptake by enhancing transcription and membrane translocation
of glucose transporters. It promotes glycolytic flux through
increasing hexokinase and phosphofructokinase activity (Robey
and Hay, 2009). Accumulating evidence shows that the activa-
tion of the Akt pathway causes increased dependency on
aerobic glycolysis (Elstrom et al., 2004; Wieman et al., 2007),
suggesting that therapeutic strategies that target the Akt
pathway can block glucose metabolism and consequently result
in tumor regression. Although numerous downstream players
involved in Akt-mediated glycolysis have been proposed,
current knowledge regarding the upstream regulators of Akt-
dependent glycolytic pathway remains limited.
In this study, we unexpectedly discover that Skp2, rather than
TRAF6, is critically involved in ErbB family-induced Akt ubiquiti-
nation, aerobic glycolysis and tumorigenesis. Importantly,
targeting glycolysis by Skp2 deficiency sensitizes Her2-positive
tumors to Herceptin treatment, highlighting the clinical value of
Skp2 targeting in breast cancer therapy.
RESULTS
Skp2 Is Responsible for EGF-Mediated Akt
Ubiquitination
To determine whether Akt ubiquitination is a common event
induced by growth factors, we examined whether Akt ubiquitina-
tion is induced by activation of epidermal growth factor (EGF)
receptor, a member of the ErbB receptor family. Indeed, in vivo
ubiquitination assay revealed that endogenous Akt ubiquitina-
tion is also induced upon EGF treatment (Figures 1A and 1E;
Figure S1F, top, available online), suggesting that Akt ubiquitina-
tion is a general event triggered by growth factors. As TRAF6 is
important for IGF-1-mediated Akt ubiquitination and activation
(Yang et al., 2009), we determined whether EGF-mediated Akt
ubiquitination and activation depend on TRAF6. To our surprise,
EGF-induced ubiquitination of Akt and phosphorylation of Akt
and Foxo1 were comparable between WT and Traf6/ MEFs
(Figures S1A and S1B), suggesting that TRAF6 is dispensable
for EGF-induced Akt activation.
Skp2 is an F-Box protein that forms a Skp2 SCF complex with
Skp1, Cullin-1 (Cul-1), and RBx1 to constitute an E3 ligase
activity that triggers protein ubiquitination and degradation
(Chan et al., 2010b; Nakayama and Nakayama, 2006). Skp2
displays oncogenic activities by regulating cell cycle progres-
sion, senescence, and metastasis (Chan et al., 2010a, 2011;
Lin et al., 2009, 2010). As we have previously demonstrated
that Akt physically interacts with Skp2 in vivo in response to
IGF-1 (Lin et al., 2009), we determined whether Skp2 is engaged
in EGF-mediated Akt ubiquitination. Although Akt ubiquitination
upon EGF stimulation was induced in WT MEFs or control-
knockdown cells, it was impaired in Skp2/ MEFs and Skp2
knockdown cells (Figures 1A and 1E and S1F, top), indicating
that Skp2 is required for EGF-induced Akt ubiquitination. More-
over, the interaction between endogenous Skp2 and Akt was
also enhanced by EGF (Figures 1B and S1C), which occurred
both in cytosol and nucleus (Figure S1D). Notably, Skp2 overex-
pression induced Akt ubiquitination in the absence of proteo-
some inhibitor, which did not cause Akt degradation (Figure 1C).
Skp2 overexpression promoted lysine (K) 63-linked, rather thanK48-linked, ubiquitination of Akt (Figure 1D). We further demon-
strated that EGF markedly promoted endogenous K63-linked,
rather than K48-linked, ubiquitination of Akt, which was dimin-
ished upon Skp2 deficiency (Figures 1E, S1E, and S1F).
Although TRAF6 knockdown reduced the basal Akt ubiquitina-
tion and IGF-1-induced Akt phosphorylation and activation,
Skp2 overexpression was still able to efficiently induce Akt
ubiquitination (Figure S1G), suggesting that Skp2 promotes Akt
ubiquitination independent of TRAF6.
Diverse Growth Factors Utilize Distinct E3 Ligase
for Akt Ubiquitination and Activation
Although TRAF6 plays a critical role in IGF-1-mediated Akt ubiq-
uitination and activation (Yang et al., 2009), this current study
shows that EGF selectively utilizes the Skp2 SCF complex to
ubiquitinate Akt. To gain further mechanistic insights into how
ErbB and IGF-1 selectivity utilize distinct E3 ligases for Akt acti-
vation, we investigated the possibility that EGF and IGF-1 may
do so by regulating their E3 ligase activities. Skp2, but not
TRAF6, interacted with EGFR and its E3 ligase activity was
enhanced upon EGF treatment, as judged by the formation of
the Skp2 SCF complex (Figures 1F and S2A). In contrast,
TRAF6 associated with IGF-1Rb and its E3 ligase activity, as
determined by TRAF6 auto-ubiquitination, was induced by
IGF-1, but not by EGF stimulation (Figures 1G and S2B). More-
over, although IGF-1 readily activated TRAF6 within 15 min, it
could not promote the formation of Skp2-SCF complex at this
early time point, although it indeed does so after 1 hr (Fig-
ure S2C), consistent with our previous observation (Lin et al.,
2009). Additionally, the endogenous expression of Skp2 was
not affected by IGF-1 stimulation within 1 hr (Figure S2D).
Thus, these results demonstrated that Skp2 is not activated at
early time points, but it is activated at longer time points.
Because IGF-1 induces the association of TRAF6 with Akt
(Yang et al., 2009) and EGF stimulates the interaction between
Skp2 and Akt (Figures 1B and S1C), we postulated that a poten-
tial mechanism responsible for this distinctive dependence on
TRAF6 and Skp2 may be due to their different binding affinity
for Akt. Indeed, we found that EGF selectively induced the inter-
action of Akt with Skp2, but not with TRAF6 (Figure S2E),
providing an explanation of why Skp2, but not TRAF6, is involved
in ErbB family-induced Akt ubiquitination.
Given that phosphorylation is a well-characterized posttrans-
lational modification that regulates protein-protein interaction,
we hypothesized that IGF-1 and EGF may regulate the interac-
tion of Akt with Skp2 or TRAF6 by inducing their phosphorylation.
In support of this notion, TRAF6 was tyrosine-, but not serine/
threonine-, phosphorylated upon IGF-1 treatment (Figure S2F,
upper and middle panels). In contrast, EGF failed to induce
TRAF6 tyrosine phosphorylation (Figure S2F, lower panel). To
further understand whether IGF-1-mediated TRAF6 phosphory-
lation may regulate TRAF6 and Akt interaction, we treated the
TRAF6 immunocomplex with phosphatase to induce TRAF6
dephosphorylation and found that IGF-1-induced TRAF6 and
Akt interaction was diminished (Figure S2G). Although Skp2
underwent tyrosine and serine/threonine phosphorylation upon
EGF stimulation, the phosphatase treatment resulted in Skp2
dephosphorylation, accompanied by Skp2 and Akt dissociationCell 149, 1098–1111, May 25, 2012 ª2012 Elsevier Inc. 1099
Figure 1. Skp2 Is Required for EGF-Mediated Akt Ubiquitination
(A) WT and Skp2/ MEFs were serum-starved, treated with or without EGF, and harvested for in vivo ubiquitination assay.
(B) 293T cells were serum-starved, treated with or without EGF and harvested for coimmunoprecipitation (co-IP) assay followed by immunoblot (IB) analysis.
(C) In vivo ubiquitination assay in 293T cells transfected with hemagglutinin (HA)-Akt1 and His-ubiquitin (His-Ub), along with Xpress-Skp2 (Xp-Skp2).
Ni-nitrilotriacetic acid (NTA) indicates nickel bead precipitate; WCE indicates whole-cell extracts. *Indicates nonspecific signal.
(D) In vivo ubiquitination assay in 293T cells transfected with various constructs.
(E) Control- and Skp2-knockdown BT-474 cells were serum-starved, treated with or without EGF, and harvested for in vivo ubiquitination assay.
(F) 293T cells were transfected with Xp-Skp2, serum-starved, treated with or without EGF, and harvested for co-IP assay followed by IB analysis.
(G) Cos1 cells were serum-starved, treated with or without IGF-1 or EGF and harvested for in vivo ubiquitination assay.
(H) In vivo ubiquitination assay in 293T cells transfected with HA-Akt1, His-Ub, along with WT Skp2 and E3-ligase dead mutants (Skp2-NES and Skp2-LRR).
See also Figures S1 and S2.(Figures S2H and S2I). Collectively, these results suggest that
various receptor tyrosine kinases (RTKs) can recruit, activate
distinct E3 ligases and regulate the interaction between Akt
and distinct E3 ligases, thereby contributing to RTK-mediated
Akt ubiquitination.1100 Cell 149, 1098–1111, May 25, 2012 ª2012 Elsevier Inc.The Skp2-SCF Complex Is Required for Akt
Ubiquitination and Activation Triggered
by ErbB Family Signaling
Whereas Skp2 overexpression promoted in vivo Akt ubiquitina-
tion, Skp2-NES and Skp2-LRR mutants, both of which have
Figure 2. Skp2 SCF Complex Is a Direct E3 Ligase for Akt
(A) Luciferase or Cul-1-silenced 293 cells transfected with various constructs were harvested for in vivo ubiquitination assay.
(B) In vivo ubiquitination assay in Luciferase or Skp1-silenced 293 cells transfected with various constructs.
(C) In vivo ubiquitination assay in various 293 knockdown cells transfected with different plasmids.
(D) GST-Akt proteins were incubated with adenosine triphosphate, E1, and E2 (both UbcH5c and Ubc13/Uev1) along with or without Flag-Skp2-SCF or
Flag-TRAF6 for in vitro Akt ubiquitination assay.
See also Figure S3.defects in Skp2 SCF E3 ligase activity (Chan et al., 2010a; Kim
et al., 2003; Lin et al., 2009), compromised this effect (Figure 1H).
Of note, the impairment of Skp2-NES mutant in promoting Akt
ubiquitination was not due to its defect in Akt binding (Fig-
ure S2J). Likewise, Skp2-mediatd in vivo Akt ubiquitination
was profoundly compromised upon Cul-1 or Skp1 knockdown
(Figures 2A and 2B). Interestingly, silencing both UbcH5c and
Ubc13, two ubiquitin-conjugating enzymes (E2s) critical for
K63-linked ubiquitination (Xia et al., 2009; Zeng et al., 2010),
attenuated Skp2-mediated Akt ubiquitination (Figure 2C).
We found that Skp2, but not Skp1 and Cul-1, could directlyinteract with Akt (Figure S3) and that Skp2 SCF complex readily
triggered in vitro Akt ubiquitination, in a manner similar to that of
TRAF6 (Figure 2D). Thus, Skp2 SCF complex is a direct E3 ligase
for Akt.
We next determined whether Skp2 SCF complex is required
for EGF-mediated Akt activation. Strikingly, EGF-induced phos-
phorylation of Akt and Foxo1 were markedly reduced in Skp2/
MEFs compared to that in WT MEFs (Figure 3A). We observed
a similar impairment in EGF-mediated Akt phosphorylation
upon Skp2, Cul-1, Skp1, UbcH5c, or Ubc13 knockdown (Figures
3B and S4A–S4C). Accordingly, these results indicate thatCell 149, 1098–1111, May 25, 2012 ª2012 Elsevier Inc. 1101
Figure 3. Skp2 SCF Complex Is Required for Akt Activation and Membrane Recruitment
(A) WT and Skp2/ MEFs were serum-starved, treated with EGF for various time points and harvested for IB analysis.
(B and C) BT-474 cells with control- and Skp2-silenced were serum-starved, treated with EGF (B) or HRG (C) for various time points and harvested for IB analysis.
(D)WT and Skp2/MEFs were serum-starved, treated with EGF for various time points, and the membrane (mem) and cytosolic (cyt) fractions were isolated for
IB analysis. The relative intensity of was quantified with ImageQuant software and normalized with the Akt levels in WT MEFs without EGF treatment.
(E) WT and Skp2/ MEFs were serum-starved, treated with EGF for 5 min and fixed for immunofluorescence assay. The arrow indicates the membrane
localization of Akt. The quantification results were shown in Figure S4G.
See also Figure S4.the Skp2 SCF complex is critical for EGF-triggered Akt phos-
phorylation and activation. To determine whether Skp2 is also
involved in Akt signaling activation by other ErbB family proteins,
BT-474 breast cancer cells were treated with Heregulin (HRG),
which is known to activate ErbB2 and ErbB3 (Agus et al., 2002;
Lee-Hoeflich et al., 2008). Notably, Skp2 knockdown also
impaired Akt phosphorylation and activation in BT-474 cells
upon HRG treatment (Figure 3C). These results suggest that
Skp2 is generally involved in Akt activation in response to ErbB
receptor signaling.1102 Cell 149, 1098–1111, May 25, 2012 ª2012 Elsevier Inc.We next examined whether Skp2 regulates the ubiquitination
of other Akt isoforms. Notably, we found ubiquitination of both
Akt1 and Akt2, but not Akt3 were induced by Skp2 overexpres-
sion, although basal ubiquitination of Akt2 was lower than that of
Akt1 (Figure S4D). Furthermore, Skp2 deficiency attenuated
EGF-mediated Akt1 and Akt2 phosphorylation (Figure S4E), indi-
cating that Skp2 is required for EGF-promoted activation of both
Akt1 and Akt2.
As TRAF6-mediated Akt ubiquitination at K8 and K14 residues
is critical for its membrane recruitment and activation (Yang
et al., 2009), we then validated whether these two sites are also
being utilized by Skp2 SCF complex. Indeed, we found that K8
and K14 residues are essential sites for Skp2-mediated Akt
ubiquitination (Figure S4F). Biochemical fractionation assay
and immunofluorescence assay revealed that EGF-induced
Aktmembrane recruitment was dramatically impaired inSkp2/
MEFs compared to that in WT MEFs (Figures 3D and 3E and
S4G).
Although the binding of Akt to PIP3 is an essential step for Akt
membrane recruitment and activation, our recent report reveals
that K63-linked ubiquitination of Akt plays a dispensable role in
Akt and PIP3 binding (Yang et al., 2009). We further excluded
the possibility that Skp2 regulates Akt membrane recruitment
and activation by affecting Akt and PIP3 binding (Figure S4H).
Although Akt dimerization is also proposed to be important for
Akt activation (Datta et al., 1995; Ku¨nstle et al., 2002; Noguchi
et al., 2007), ubiquitination-dead mutant of Akt displayed similar
capability to form Akt dimer as WT Akt did (Figure S4I), suggest-
ing that Akt ubiquitination does not regulate Akt dimerization.
Skp2 Regulates Glycolysis through Inducing Akt
Ubiquitination and Activation
Cancer cells evolve to develop a mechanism that increases
glucose uptake and glycolysis to generate higher ATP levels,
a phenomenon called Warburg effect (Warburg, 1956). The
Warburg effect is critically regulated by Akt, which is highly acti-
vated in human cancers (Elstrom et al., 2004; Manning and Cant-
ley, 2007; Plas and Thompson, 2005; Robey and Hay, 2009). As
Skp2 orchestrates Akt ubiquitination and activation, it is con-
ceivable that Skp2 may regulate glucose uptake and glycolysis.
Indeed, we found that Skp2 knockdown suppressed glucose
uptake and glycolysis in breast cancer cells upon EGF or HRG
stimulation, as determined by lactate production and glucose
incorporation assays (Figures 4A and 4B and S5A–S5C and
S5E), in a manner similar to that of PI3K/Akt inhibition (Figures
4B and 4C and S5D and S5F). To further investigate whether
Skp2 regulates in vivo glycolysis and breast cancer develop-
ment, we monitored the impact of Skp2 expression on in vivo
glucose uptake and subsequent tumor growth in a xenograft
model bearing Her2-overexpressing breast tumors. Although
in vivo glucose uptake was enriched in control-silenced breast
tumors, it was profoundly reduced upon Skp2 knockdown,
which correlated with tumor suppression upon Skp2 silencing
(Figures 4D–4G). Accordingly, Skp2 promotes in vivo glycolysis
and breast cancer development.
Intriguingly, introduction of Myr-Akt, a constitutively active
form of Akt, rescued the defect in lactate production of Skp2-
knockdown cells in the presence of EGF or HRG (Figures 5A
and S6A and S6B), suggesting that Skp2 regulates glycolysis
in cancer cells through modulating Akt activation. Because Akt
regulates glucose uptake by inducing gene expression and
membrane translocation of Glut1 (glucose transporter type 1),
a predominant glucose transporter expressed in most cell types
(Barthel et al., 1999; Wieman et al., 2007), we examined whether
Glut1 is a downstream target of Skp2 in regulating glycolytic
phenotype. As expected, Skp2 deficiency reduced Glut1 tran-
scription and protein expression in breast cancer cells, recapit-
ulating the phenotype driven by Akt inactivation (Figures 5B,5C, and 5F and S5E–S5G). Importantly, we found that Glut1
protein expression in both membrane fraction and total cell
extracts was markedly induced by EGF in control-knockdown
cells; however, this induction was impaired in Skp2-deficient
cells (Figures 5D and 5E and S6C). The inhibition of Glut1 protein
expression in Skp2-knockdown cancer cells was also rescued
by the introduction of Myr-Akt (Figure 5F), underscoring that
Skp2 regulates Glut1 expression through Akt activation.
To further support our notion that Skp2 regulates glycolysis
through Akt ubiquitination, we introduced Akt-Wt, Myr-Akt and
Akt-K8R/K14R in Skp2-deficient cells to investigate their effects
on glucose metabolism. Notably, although the introduction of
Akt-Wt or Myr-Akt rescued the defect in lactate production of
Skp2-knockdown cells in the presence of EGF or HRG, Akt-
K8R/K14R mutant failed to do so (Figures 5G and S6A and
S6B). These results indicate that Skp2 controls glycolysis in
cancer cells through regulating Akt ubiquitination and activation.
Skp2 Loss Attenuates Akt Activity, Glut1 Expression,
and Mammary Tumor Development inMMTV-Neu Mice
As Skp2 is critical for ErbB receptor signaling, we examined the
role of Skp2 loss in Akt activation, Glut1 expression, and tumor-
igenesis in MMTV-Neu transgenic mice, which develop primary
and metastatic breast cancer (Oshima et al., 2004). Kaplan-
Meier survival analysis revealed that Skp2 deficiency sig-
nificantly prolonged the survival ofMMTV-Neu mice (Figure 6A).
Notably, Skp2 deficiencymarkedly delayed breast cancer devel-
opment and reduced breast tumor volume in MMTV-Neu mice,
thereby restricting breast cancer metastasizing to the lungs
(Figures 6B–6E). Skp2 loss also inhibited in vivo Akt activation
and Glut1 expression in MMTV-Neu mice, correlated with the
reduced Ki-67 expression of MMTV-Neu mice (Figure 6F).
Collectively, Skp2 deficiency inhibits Akt activation and Glut1
expression in vitro and in vivo, in turn repressing breast cancer
development.
Skp2 Serves as a Marker for Poor Prognosis
in Her2-Positive Breast Cancer Patients
Because Skp2 regulates Akt activation and tumorigenesis in
MMTV-Neu mouse model, we next investigated whether Skp2
correlates with Akt activation and serves as a marker for poor
prognosis in Her2-positive breast cancer patients. For this
purpose, we have retrospectively identified 213 consecutively
treated breast cancer patients that received modified radical
mastectomy with curative intent and without neither pre- nor
postoperative adjuvant chemotherapy and/or radiation therapy.
Among them, 80 cases were Her2-positve (defined as 3+),
whereas 132 were Her2-negative (defined as 0 to 2+). In these
80 cases of Her2-positive breast carcinomas, Skp2 overexpres-
sion was significantly correlated with numerous adverse clinico-
pathological factors, including increments of primary tumor
status (pT, p = 0.05), nodal metastasis (pN, p = 0.012), and stage
(p = 0.026) (Table S1). Skp2 expression also significantly corre-
lated with the upregulation of pAkt (S473) (p < 0.001) (Figure 7A
and Table S1). We next asked the question whether Skp2
expression also correlates with both Akt1 and Akt2 phosphory-
lation in breast tumors. Interestingly, phosphorylation of both
Akt isoforms was higher in Skp2-high tumors than that inCell 149, 1098–1111, May 25, 2012 ª2012 Elsevier Inc. 1103
Figure 4. Skp2 Regulates Glucose Uptake and Glycolysis In Vitro and In Vivo
(A) Lactate production was measured in BT-474 cells with Luciferase and Skp2 knockdown.
(B) Glucose uptake was measured in BT-474 cells with Luciferase and Skp2 knockdown. Cells treated with or without LY294002 were grown in the presence of
the fluorescent analog NBDG for various time points, and glucose uptake was quantified using FACS analysis.
(C) Lactate production was measured in BT-474 cells treated with or without LY294002.
(D) Representative PET/CT images in nudemice bearing breast tumors with luciferase- or Skp2-knockdown.White dotted lines indicate area of the breast tumors
and black dotted lines indicate area of muscle tissues that were analyzed for in vivo glucose uptake.
(E and F) Glucose uptake was expressed as standard uptake value (SUV) ratio (E) or as percent of injected dose per gram (F) of labeled [18F] FDG-glucose
incorporation inmice bearing Luciferase- or Skp2-silenced breast tumors. Glucose uptake in breast tumorswas normalized withmuscle, thymus or liver tissues in
each mouse. The quantified results are presented as means ± SD (n = 5).
(G) Breast tumor development in nude mice bearing breast tumors with luciferase- or Skp2-knockdown (n = 5). The arrow indicates the time point for in vivo
glucose uptake analysis. **p < 0.01.
See also Figure S5.Skp2-low tumors, and Skp2 expression nicely correlated with
Her2 levels in breast tumors (Figure 7B). Our results suggest
that Skp2 upregulation in Her2-positve breast tumors may
contribute to activation of Akt1 and Akt2, thereby promoting
breast cancer progression in Her2-positive breast cancer
patients.1104 Cell 149, 1098–1111, May 25, 2012 ª2012 Elsevier Inc.As Akt-mediated Skp2 S72 phosphorylation stabilizes Skp2
expression and enhances its E3 ligase activity (Gao et al.,
2009; Lin et al., 2009), we asked the question whether this
Akt-mediated phosphorylation of Skp2 may serve as a positive
feedback loop for Akt ubiquitination. Indeed, we found that the
Skp2 S72A mutant defective in Akt-mediated phosphorylation
Figure 5. Skp2 Regulates Glycolysis through Promoting Akt Ubiquitination and Activation
(A) Lactate productionwas determined in BT-474 cells with luciferase, Skp2 knockdown, or Skp2 knockdown plusMyr-Akt overexpression upon EGF stimulation.
(B) Real-Time PCR analysis of Glut1 mRNA levels in BT-474 cells or MDA-MB-468 cells with luciferase or Skp2 knockdown.
(C) Real-Time PCR analysis of Glut1 mRNA Levels in WT and Skp2/ MEFs.
(D) Cos1 cells with luciferase or Skp2 knockdown were serum-starved, treated with EGF for various time points and harvested for the isolation of membrane and
cytosolic fractions, followed by IB analysis.
(E) Cos1 cells with LUCIFERASE or Skp2 knockdown were serum-starved, treated with EGF for various time points and harvested for IB analysis.
(F) IB analysis of Glut1 protein expressions in whole cell extracts (WCE) or membrane fractions (Mem) of BT-474 cells with luciferase, Skp2 knockdown, or Skp2
knockdown plus Myr-Akt overexpression.
(G) Lactate production was measured in Luciferase- and Skp2-silenced BT-474 cells transfected with various constructs as indicated upon EGF stimulation. The
quantified results are presented as means ± SD (n = 3). *p < 0.05; **p < 0.01.
See also Figure S6.
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Figure 6. Skp2 Deficiency Restricts In Vivo Akt Activation and Mammary Tumor Development upon Neu Overexpression
(A) Kaplan-Meier plot analysis of cumulative disease-free survival of WT, MMTV-Neu, and MMTV-Neu/Skp2/ mice.
(B) Kaplan-Meier plot analysis of tumor-free incidence of WT, MMTV-Neu, and MMTV-Neu/Skp2/ mice.
(C) The percentage ofmice that developmammary tumorwas analyzed from a cohort ofWT,MMTV-Neu, andMMTV-Neu/Skp2/mice at age around 10months
(WT, n = 10; MMTV-Neu, n = 13; MMTV-Neu/Skp2/, n = 10).
(D) Mammary tumors were obtained and weighed fromMMTV-Neu andMMTV-Neu/Skp2/mice at the age around 10months (MMTV-Neu, n = 11;MMTV-Neu/
Skp2/, n = 10). The quantified results are presented as means ± SD. Arrows indicate mammary tumors. **p < 0.01.
(E) The percentage of mice that develop lung metastasis was analyzed from a cohort ofWT,MMTV-Neu, andMMTV-Neu/Skp2/mice at age12 months (WT,
n = 10; MMTV-Neu, n = 11; MMTV-Neu/Skp2/, n = 9).
(F) Histological and quantification analysis of pAkt, Glut1, and Ki-67 protein expression in MMTV-Neu and MMTV-Neu/Skp2/ mice. Scale bar represents
200 mm. All p value < 0.001 by using Mann-Whitney U test, except the p value for Glut1 expression between localized and metastatic MMTV-Neu/Skp2/
(p = 0.105).
1106 Cell 149, 1098–1111, May 25, 2012 ª2012 Elsevier Inc.
Figure 7. Skp2 Deficiency Prolongs Survival of Her2-Positve Patients and Confers Herceptin Sensitivity in Her2-Positive Cells and Tumors
(A) Histological and quantification analysis of pAkt expressions in Her2-positive patients with low or high expression of Skp2. Scale bar represents 200 mm. All
p value < 0.001 by using Mann-Whitney U test.
(B) Breast tumors and normal breast tissues were extracted and subjected for IP assay, followed by IB analysis.
(C) Kaplan-Meier plot analysis of metastasis-free survival of 80 cases of Her2-positive patients with low or high expression of Skp2.
(D) Kaplan-Meier plot analysis of metastasis-free survival of 132 cases of Her2 low-expressing patients with low or high expression of Skp2.
(E) Cell growth inhibition assay and IB analysis in BT-474 cells with luciferase or Skp2 knockdown. BT-474 cells were treated with various doses of Herceptin for
6 days and cell numbers were counted using hemocytometer.
(F) Tumor volume of Her2-positive tumors with or without Skp2 silencing upon treatment with IgG or Herceptin. Tumor volume at various time points of treatment
is presented as percentage of original tumor size (200 mm3) at day zero of treatment. The quantified results are presented as means ± SD (n = 6). **p < 0.01.
(G) BT-474 cells with luciferase or Skp2 knockdownwere transfectedwith various plasmids, treatedwith various doses of Herceptin and viable cell numbers were
counted using hemocytometer. The quantified results are presented as means ± SD (n = 3). *p < 0.05; **p < 0.01.
(H) The working model of Skp2 in ErbB family-regulated Akt activation, glycolysis, and tumorigenesis.
See also Figure S7 and Tables S1, S2, S3, and S4.
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reduced its ability to promote Akt ubiquitination compared toWT
Skp2 (Figure S7A). Moreover, we found that the Skp2-S72A
mutant was defective in promoting Akt phosphorylation and
activation in breast cancer cells (Figure S7B). Interestingly, the
level of Skp2 S72 phosphorylation was upregulated and corre-
lated with pAkt levels in multiple breast cancer cell lines (Fig-
ure S7C), suggesting that Skp2 phosphorylation is upregulated
in breast cancer cells and correlates with Akt activation. More-
over, Skp2 S72A mutant compromised its ability to promote
breast cancer cell migration and invasion compared to that of
WT Skp2 (Figures S7D and S7E), correlated with its defect in
promoting Akt ubiquitination and activation (Figures S7A and
S7B). Future work would be required to further understand
whether Skp2 phosphorylation orchestrates breast cancer
metastasis.
In the univariate survival analysis, Skp2 (p = 0.0048 by contin-
uous scoring) and pAkt (S473) (p = 0.0134) overexpression,
together with pT status (p < 0.0001), pN status (p = 0.0016),
and stage (p < 0.0001) effectively predicted inferior metastasis-
free survival (p = 0.0002 by binary cut-offs) (Figure 7C and Table
S2). In the multivariate analysis, although Skp2 overexpression
remained prognostically significant for metastasis-free survival
in Her2-positive breast cancer patients (p = 0.0343 by contin-
uous scoring in multivariate analysis, p = 0.0048 by continuous
scoring in univariate analysis) (Table S2), this prognostic effect
was not significant in our 132 in-house Her2-negative breast
cancers (p = 0.1065 by continuous scoring in univariate analysis
and p = 0.0891 by binary cut-offs) (Figure 7D and Table S3).
Moreover, Skp2 level did not significantly correlate with pAkt
(S473) level in Her2-negative breast cancer samples (p =
0.672, Table S4). To further strengthen our notion that Skp2
serves as a biomarker for poor prognosis, we have analyzed
the correlation between Skp2 and Her2mRNA levels in NKI data-
set (van de Vijver et al., 2002) and found that high Skp2 mRNA
level significantly predicted inferior distal metastasis-free
survival (p = 0.0018) in Her2 overexpressing breast cancer, but
not in Her2 low expressing breast cancer (p = 0.1364) (Figures
S7F and S7G). Our results collectively suggest that the status
of Skp2 expression can predict survival outcome of Her2-
positive breast cancer patients.
Skp2 Deficiency Enhances Herceptin Sensitivity
in Her2-Positive Cancer Cells and Tumors
Herceptin is the standard treatment for Her2-positive breast
tumors that substantially improves the clinical outcomes of these
patients. However, there are still a number of patients that
display intrinsic or acquired resistance to this treatment. The
discordant Herceptin responses among Her2-positive patients
are possibly due to the heterogeneous nature of tumors. As
Skp2 deficiency or knockdown inhibits glycolysis in mouse
tumor models (Figures 4D–4F and 6F), we examined whether
Skp2 targeting sensitizes Herceptin response in Her2-positive
cancer cells and tumors. Indeed, the Herceptin sensitivity was
significantly enhanced in Skp2-silenced cells (Figures 7E and
S7H). In preclinical mouse model, although Herceptin by itself
inhibited tumor growth, it did not cause tumor shrinkage (Fig-
ure 7F). Strikingly, Skp2 silencing in conjunction with Herceptin
treatment resulted in substantial tumor regression (Figure 7F),1108 Cell 149, 1098–1111, May 25, 2012 ª2012 Elsevier Inc.highlighting that Skp2 is an appealing therapeutic target to
combine with Herceptin for anticancer treatment.
To support the notion that Skp2 regulates Herceptin resis-
tance through promoting Akt ubiquitination and activation, we
introduced Akt-K8R/K14R, Akt-WT, and Myr-Akt in Skp2-
silenced cells to examine their effects on Herceptin sensitivity.
Notably, overexpression of WT Akt or Myr-Akt prevented height-
ened Herceptin sensitivity in Skp2-silecned cells, whereas
Akt-K8/K14R overexpression failed to do so (Figure 7G),
elucidating that Skp2 regulates Herceptin resistance through
promoting Akt ubiquitination.
DISCUSSION
Our results reveal several unexpected findings with important
clinical implications. We identify that the Skp2 SCF complex is
a crucial E3 ligase for promoting Akt ubiquitination and activa-
tion, thereby resulting in elevated glycolysis and tumorigenesis
in response to ErbB receptor signaling (Figure 7H). Importantly,
we provide preclinical evidence demonstrating that targeting
glycolysis drastically benefits therapeutic outcomes for current
anticancer treatments.
Different Growth Factors Utilize Distinct E3 Ligases
for Akt Ubiquitination and Activation
Our current and previous findings establish that K63-linked ubiq-
uitination of Akt is a general event triggered by growth factors
and cytokines, such as IGF-1, EGF and interleukin-1, and plays
a critical role in Akt membrane recruitment and activation.
Although TRAF6 is required for IGF-mediated Akt ubiquitination
and activation, our current study reveals that Skp2, but not
TRAF6, is selectively engaged in Akt ubiquitination and activa-
tion driven by activation of ErbB family receptors. Given that
other growth factors like PDGF and FGF are known to activate
Akt signaling and we also revealed that Skp2 increased associ-
ation with Akt upon stimulation of PDGF, but not FGF (data not
shown), it remains to be determined whether Skp2 is involved
in PDGF-mediated Akt ubiquitination and activation.
Skp2 SCF Complex Regulates Nonproteolytic
K63-Linked Ubiquitination
Skp2 SCF complex is known to play a critical role in cell cycle
regulation and tumorigenesis by promoting ubiquitination and
degradation of p27 and p21 (Chan et al., 2010b; Lin et al.,
2010; Nakayama and Nakayama, 2006). We identify that Akt is
a Skp2 SCF substrate, whose ubiquitination does not lead to
degradation. Thus, Akt is a substrate of Skp2 SCF complex
that undergoes K63-linked ubiquitination. As Skp2 and other
F-box proteins are long thought to promote ubiquitination and
degradation of their substrates, our current study challenges
this dogma by identifying Akt as a nonproteolytic substrate for
Skp2. In light of this unexpected finding, we speculate that there
may bemore Skp2 protein substrates undergoing nonproteolytic
K63-linked ubiquitination.
Skp2 Regulates Aerobic Glycolysis, the Warburg Effect
Elevated aerobic glycolysis is a hallmark in various tumor origins,
as evidenced by the wide application of PET scan in clinical
diagnosis for detecting cancer cells with actively glucose uptake
(Zhu et al., 2011). Thus, identifying factors that control cancer
cell glycolysis not only can advance current knowledge of
how tumor cells seize glucose metabolism to acquire survival
advantage, but also provide innovative approaches for cancer
therapy. Our present study uncovers an unrecognized function
of Skp2 in glucose metabolism. We identify Skp2 as a critical
regulator for glycolysis by regulating Akt ubiquitination and
activation.
Hypoxia-inducible factor-1a (HIF-1a) can activate transcrip-
tion of genes encoding Glut1, Hexokinase II, Lactate dehydroge-
nase A (LDH-A), as well as pyruvate dehydrogenase kinase 1
(PDK1). As such, HIF-1a accumulation stimulates glucose
metabolism by increasing both glucose consumption and lactate
production as PDK1 inhibits conversion of pyruvate to acetyl-
CoA and suppresses oxidative phosphorylation. Because acti-
vation of Akt/mTOR is known to enhance HIF-1a translation
(Jiang et al., 2001; Majumder et al., 2004), it is likely that Skp2
may also upregulate HIF-1a translation and induces HIF-1-
dependent glycolysis through the Akt/mTOR pathway.
In addition to the Skp2-Akt axis, we cannot rule out the possi-
bility that Skp2 may also cooperate with other key regulators to
participate in glucose metabolism or other metabolic pathways.
For instance, Myc overexpression increases transcription of
many metabolic enzymes, including glycolytic enzymes (Glut1
and Hexokinase II), LDH-A, and several enzymes required for
nucleotide biosynthesis (DeBerardinis et al., 2008; Osthus
et al., 2000; Shim et al., 1997). Because Skp2 cooperates with
Myc to activate various Myc target genes involved in cell cycle
transition or cell migration (Chan et al., 2010a; Kim et al., 2003;
von der Lehr et al., 2003), it implies that Skp2 may participate
in Myc-dependent metabolic processes through inducing the
transcription of metabolic target genes. Future study will be
needed to explore this possibility.
Skp2 Is a Marker for Poor Survival Outcomes and
a Potential Therapeutic Target for Her2-Positive Breast
Cancer
The PI3K/Akt is one of the most important oncogenic pathways
activated downstream of Her2/ErB2 in cancers (Hynes and
MacDonald, 2009). Our study reveals that Skp2 overexpression
correlates with Akt activation and poor survival outcomes in
Her2-posivtive breast cancer patients, but not in Her2-negative
ones, supporting the in vivo relevance of Skp2 in ErbB family
receptor-induced Akt activation and breast cancer progression.
Our findings demonstrating the pronounced defect of Skp2
silencing in glucose uptake of Her2-overexpressing tumor
suggests that Skp2 targeting is a promising strategy for inhibiting
glycolysis and cancer (Figures 4D–4G). Because Skp2 also
recognizes and promotes degradation of p27 and p21 (Bornstein
et al., 2003; Nakayama et al., 2000; Nakayama and Nakayama,
2006), it is possible that downregulation of p27 or p21 may
also contribute to tumor progression or poor survival outcome
driven by Skp2 overexpression.
In addition to Her2/Neu overexpression, Skp2 loss also
impacts tumorigenesis driven by Pten, pRB, and p19ARF inacti-
vation in various transgenic mouse models (Lin et al., 2010;
Wang et al., 2010). It is possible that Skp2 silencing may globallyinhibit glycolysis driven by various oncogenic insults through
regulating Akt activation or other mechanisms. Our findings
along with these recent reports thereby suggest that targeting
glycolysis pathways can be an important therapeutic approach
for cancer treatment.
Multiple genetic or epigenetic alterations have been revealed
in various cancer types. Therefore, designing a strategy that
universally targets fundamental features of cancer cells, such
as glycolysis, may serve as a valuable anticancer approach.
Several small molecules that pharmacologically inactivate
glycolysis have emerged and shown promising anticancer
activities as single agent or in combination with other thera-
peutic modalities (Pelicano et al., 2006; Vander Heiden et al.,
2009). In support of this notion, our discovery reveals that
Skp2 silencing as a therapeutic strategy to inactivate glycolysis
can sensitize Her2-positive cells/tumors response to Herceptin
(Figures 7E–7G and S7H). As such, our study provides a proof-
of-principle that targeting glycolysis is a compelling therapeutic
strategy as a single or a combinatory therapy for cancer
treatment.
EXPERIMENTAL PROCEDURES
Mice, Cell Culture, and Reagents
MMTV-Neu and Skp2/ mice were described (Lin et al., 2010; Nakayama
et al., 2000; Oshima et al., 2004). Mouse embryonic fibroblasts (MEFs) from
wild-type and Skp2/ mice were prepared as previously described (Lin
et al., 2004, 2010). All manipulations were performed under IACUC approval
protocol. 293T, Cos1, BT-474, and MDA-MB-231 cells were cultured in
DMEM containing 10% fetal bovine serum (FBS). (His)6-ubiquitin, (His)6-ubiq-
uitin-K48R and (His)6-ubiquitin-K63R, GST-Akt1, HA-Akt1 constructs was
described previously (Yang et al., 2009). Skp2-LRR construct was from
W. Tansey. Herceptin was a gift from Dr. M.H. Lee.
In Vivo and In Vitro Ubiquitination Assay
In vivo and in vitro ubiquitination assays were performed as described (Lin
et al., 2009; Yang et al., 2009). For in vivo ubiquitination assay, 293T cells
were transfected with the indicated plasmids for 48 hr and lysed by the dena-
tured buffer (6 M guanidine-HCl, 0.1MNa2HPO4/NaH2PO4, 10mM imidazole).
The cell extracts were then incubated with nickel beads for 3 hr, washed, and
subjected to immunoblotting analysis. For in vitro ubiquitination assays,
recombinant GST and GST-Akt proteins were purified from the bacterial
lysates of BL21 competent cells. Flag-Skp2 SCF complex and Flag-TRAF6
were expressed in 293T cells, immunoprecipitated by anti-Flag antibody,
and eluted from Protein A/G beads using Flag peptides according to manufac-
turers’ standard procedures. Purified GST, GST-Akt, Flag-SCF, and Flag-
TRAF6 proteins were incubated for 3 hr at 37C in 20 ml of reaction buffer
(20 mM HEPES [pH 7.4], 10 mM MgCl2, 1 mM DTT, 59 mM ubiquitin, 50 nM
E1, 850 nM of Ubc13/Uev1a, 1 mM ATP, 30 mM creatine phosphate, and
1 U of creatine kinase). After incubation, protein mixtures were diluted in
RIPA buffer and the supernatant fluid was precleared with Protein A/G beads
for 1 hr, and immunoprecipitated overnight with anti-Flag antibody, after which
Protein A/G beads were added for an additional 1 hr. Beads were washed four
times with E1A Buffer. Proteins were eluted in SDS-sample buffer and sub-
jected to immunoblotting analysis. All animal experiments were performed
under IACUC approval protocol.
Glucose Uptake Assay
Cells were seeded in 60 mm plates. Twenty-four hours later, cells were re-
freshed with serum-starved (0.1% FBS) and glucose-free DMEM. Sixteen
hours later, cells treated with or without 10 mM LY294002 were grown in the
presence of 50 mM 2-NBDG for 30 min and 60 min, respectively, and glucose
uptake was quantified using FACS analysis.Cell 149, 1098–1111, May 25, 2012 ª2012 Elsevier Inc. 1109
Lactate Production Assay
Cells were plated in 24-well plate and cultured overnight. After pretreated with
or without 10 mM LY294002, cells were treated with EGF (50 ng/ml) for 8 hr.
Culture medium was removed from cells and lactate concentration was deter-
mined using lactate test strips and Accutrend Lactate analyzer (Accutrend
Lactate, Roche). Next, cells were harvested, stained with trypan blue, and
viable cell numbers were counted directly under the microscope using hemo-
cytometer. Last, the rate of lactate production were determined (lactate
production rate = lactate concentration/cells/time) and normalized with the
rate detected in control group.
In Vivo Tumorigenesis Assay and In Vivo Glucose Uptake Assay
For in vivo tumorigenesis assays, 5 3 106 of BT-474-M1 cells were injected
into mammary fat pad of age-matched athymic female nude mice (five mice
for each group). Tumor size was measured weekly with a caliper, and tumor
volume was determined with the standard formula: L 3 W2 3 0.52, where L
is the longest diameter and W the shortest diameter. While developed tumors
reached to the volume 200 mm3, mice were imaged and analyzed with [18F]
FDG for in vivo glucose uptake. [18F]FDG were administered via a single tail-
vein injection and PET/CT images were scanned and collected on Inveon
CT/PET system (Siemens). Mice were awake during the uptake period and
maintained on a heating pad. Images were then reconstructed using two-
dimensional ordered subsets expectation maximization (OSEM) algorithm.
PET and CT image fusion and image analysis were performed using software
ASIPro 5.2.4.0 (Siemens). For Herceptin treatment, 83 106 of BT-474-M1 cells
were injected into mammary fat pad of age-matched athymic female nude
mice (five mice for each group). While developed tumors have reach to the
volume around 200 mm3, mice were injected with 5 mg/kg of Herceptin or
vehicle control (IgG) intraperitoneally once per week, and tumor size was
measured weekly with a caliper.
Cell Growth Assay
For Herceptin administration, 8 3 103 of BT-474 cells with control, Skp2
knockdown were seeded in 12-wells in triplicate, 24 hr later, treated with
Herceptin (refreshed every 2 days). Six days later, cells were harvested,
stained with trypan blue, and viable cells were counted directly under the
microscope using hemocytometer.
Immunohistochemistry and Scoring
The procedures of immunohistochemical studies were performed as previ-
ously described (Huang et al., 2006). In brief, sections were cut onto an adhe-
sive-coated glass slides at 3-mm thickness. For stainings in human samples,
the slides were incubated with primary antibodies targeting Her-2 (Thermo
Scientific, Clone SP3, 1:100), Skp2 (Invitrogen, clone 2C8D9, 1:100), and pAk-
t(Ser473) (Cell Signaling, clone D9E, 1:25). The slides from mouse samples were
incubated with primary antibodies for pAkt(Ser473) (Cell Signaling, clone D9E,
1:25), Ki-67 (Abcam, polyclonal, 1:200), and Glut1 (Abcam, clone SPM498,
1:200), respectively. Primary antibodies were detected using the ChemMate
DAKO EnVision kit (DAKO, K5001). The slides were incubated with the
secondary antibody for 30 min and developed with 3,3-diaminobenzidine for
5 min. Incubation without the primary antibody was used as a negative control.
Immunoexpression was scored by two pathologists (C.F.L and H.Y.H.) using
a multiheaded microscope to reach a consensus for each case. The staining
was evaluated based on a combination of both the percentage and intensity
of positively stained tumor cells to generate an H-score, which was calculated
using the following equation: H-score = SPi (i + 1), where i is the intensity of the
stained tumor cells (0 to 4 +), and Pi is the percentage of stained tumor cells for
each intensity.
Statistical Analysis
Statistical analyses were performed using the SPSS 14 software package. For
human breast samples, the Mann-Whitney U test was used to assess the
differential expression level of Skp2 and pAkt(S473) expression in relation to
Her-2 expression status. The Spearman’s rank correlation coefficient was
used to clarify the association between Skp2 expression to clinicopathological
variables and pAkt(Ser473) expression levels. The endpoint analyzed was distal
metastasis-free survival, calculated from the starting date of surgery to the1110 Cell 149, 1098–1111, May 25, 2012 ª2012 Elsevier Inc.date of event. The median period of follow-up was 103 months (range, 6–
143). Survival analysis was performed using the Cox proportional hazards
model. Survival curves were plotted using the Kaplan-Meier method, and
log-rank tests were performed to evaluate prognostic differences between
groups for categorical variables. For mouse samples, the expression levels
of pAkt, Ki-67, and Glut1 between various groups were assessed by using
Mann-Whitney U test. For all analyses, two-sided tests of significance were
used with p = <0.05 considered significant.
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